Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.63 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | P2RX7 | Q99572 | 9/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10094997 | 0.94 | CYP3A4 (0.64) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL10094979 | 0.92 | CYP3A4 (0.72) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL10094998 | 0.92 | CYP3A4 (0.64) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL10095025 | 0.90 | CYP3A4 (0.64) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL10094994 | 0.89 | CYP3A4 (0.64) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL10095002 | 0.89 | CYP3A4 (0.64) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL10095023 | 0.87 | CYP2C9 (0.69) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL10095027 | 0.87 | CYP3A4 (0.62) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL10094982 | 0.87 | CYP3A4 (0.68) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL10095001 | 0.86 | CYP3A4 (0.65) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303876-B1 | DIKETO AZOLOPIPERIDINES AND AZOLOPIPERAZINES AS ANTI-HIV AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8124615-B2 | Diketo substituted pyrrolo[2,3-C]pyridines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124615-B2 | Diketo substituted pyrrolo[2,3-C]pyridines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110212971-A1 | DIKETO FUSED AZOLOPIPERIDINES AND AZOLOPIPERAZINES AS ANTI-HIV AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| US-20110212971-A1 | DIKETO FUSED AZOLOPIPERIDINES AND AZOLOPIPERAZINES AS ANTI-HIV AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| US-7960406-B2 | Diketo substituted pyrrolo[2,3-c] pyridines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960406-B2 | Diketo substituted pyrrolo[2,3-c] pyridines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100009993-A1 | Diketo Fused Azolopiperidines and Azolopiperazines as Anti-HIV Agents | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-14 | — | — | US | disclosed |
| US-20100009993-A1 | Diketo Fused Azolopiperidines and Azolopiperazines as Anti-HIV Agents | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-14 | — | — | US | disclosed |
| WO-2009158394-A1 | DIKETO AZOLOPIPERIDINES AND AZOLOPIPERAZINES AS ANTI-HIV AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212971-A1 | DIKETO FUSED AZOLOPIPERIDINES AND AZOLOPIPERAZINES AS ANTI-HIV AGENTS | DHFR, DHPS, DCK | CYP3A4 44/4885CYP2C9 1097/4885CYP2D6 294/4885 |
| US-20100009993-A1 | Diketo Fused Azolopiperidines and Azolopiperazines as Anti-HIV Agents | DHFR, DHPS, DCK | CYP3A4 44/4885CYP2C9 1097/4885CYP2D6 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.